Novo Nordisk Other Non-Current Liabilities 2010-2024 | NVO

Novo Nordisk other non-current liabilities for the quarter ending December 31, 2024 were $1.273B, a 28.19% increase year-over-year.

  • Novo Nordisk other non-current liabilities for 2024 were $1.273B, a 28.19% increase from 2023.
  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
  • Novo Nordisk other non-current liabilities for 2022 were $0.664B, a 11.83% decline from 2021.

Novo Nordisk Other Non-Current Liabilities 2010-2024 | NVO

  • Novo Nordisk other non-current liabilities for 2024 were $1.273B, a 28.19% increase from 2023.
  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
  • Novo Nordisk other non-current liabilities for 2022 were $0.664B, a 11.83% decline from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$827.9B
Johnson & Johnson (JNJ)$384.4B
AbbVie (ABBV)$354.6B
Roche Holding AG (RHHBY)$262.5B
Merck (MRK)$221.8B
Novartis AG (NVS)$219.3B
Pfizer (PFE)$146.8B
Sanofi (SNY)$137.4B
Bayer (BAYRY)$22.6B
Innoviva (INVA)$1.1B